The short term effects were studied of several monoaminergic precursors which were administered to rhesus-monkeys because of their ready passage through the blood/brain barrier and, hence, because of their ability to activate monoamine neurons, as well as apomorphine in the release of growth hormone and sleep. An acute elevation in plasma growth hormone (GH) concentration was caused by intravenous injections of L-dihydroxyphenylalanine (L-dopa) at 15 to 200mg/kg and 5-HTP-monohydrate (5-HTP) at 20 to 60mg/kg. Behavioral and electroencephalographic (EEG) slow wave sleep were induced by 5- HTP. A delayed and smaller elevation was induced by L-tryptophan injected at 50 to 100mg/kg doses. No induced GH release, behavioral sleep or change in the EEG activity followed dosing with apomorphine at 50 to 75 micrograms. Both L-dopa and 5-HTP were potent stimuli for the rapid release of GH in the rhesus-monkey. GH release after L-dopa infusion ranged from 14 to 39 nanograms per milliliter (ng/ml) and after 5-HTP infusion ranged from 11 to 35ng/ml, however, these elevations were not dose related. No evidence was found that hypoglycemia was the stimulus for the GH release. The delayed peaks of GH that followed L-tryptophan infusion may have been due to a release of insulin which then lowered blood sugar. However, it is more likely that these secretory episodes occurred independent of blood glucose changes, reflecting a normally occurring spontaneous release of GH unrelated to L-tryptophan administration. While the mechanism by which these compounds may exert such an effect is not known, both catecholaminergic and serotoninergic pathways were implicated.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.